FLT3 exon 14 ins FLT3 D835Y
|
hematologic cancer
|
sensitive
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lestaurtinib (CEP-701) inhibited proliferation of transformed cells expressing FLT3-ITD and FLT3 D835Y in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D835Y
|
hematologic cancer
|
resistant
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835Y demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L
|
hematologic cancer
|
resistant
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 F691L demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D839G
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D839G were sensitive to Rydapt (midostaurin) treatment in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 Y842H
|
hematologic cancer
|
sensitive
|
Momelotinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Momelotinib (CYT387) decreased phosphorylation of Flt3 and Stat5 and inhibited proliferation of transformed cells expressing FLT3-ITD and FLT3 Y842H in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D835Y
|
hematologic cancer
|
sensitive
|
Momelotinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Momelotinib (CYT387) decreased phosphorylation of Flt3 and Stat5 and inhibited proliferation of transformed cells expressing FLT3-ITD and FLT3 D835Y in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 Y842H
|
hematologic cancer
|
sensitive
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 Y842H were sensitive to Crenolanib (CP-868596) treatment in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D839G
|
hematologic cancer
|
resistant
|
Sorafenib
|
Preclinical - Biochemical |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D839G demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L FLT3 D835Y
|
hematologic cancer
|
resistant
|
Momelotinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 F691L and D835Y demonstrated resistance to Momelotinib (CYT387) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D839G
|
hematologic cancer
|
sensitive
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lestaurtinib (CEP-701) inhibited proliferation of transformed cells expressing FLT3-ITD and FLT3 D839G in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 Y842H
|
hematologic cancer
|
resistant
|
Pacritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 Y842H demonstrated resistance to Vonjo (pacritinib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 Y842H
|
hematologic cancer
|
sensitive
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lestaurtinib (CEP-701) inhibited proliferation of transformed cells expressing FLT3-ITD and FLT3 Y842H in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L FLT3 Y842H
|
hematologic cancer
|
resistant
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD, FLT3 F691L, and FLT3 Y842H demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D835V
|
hematologic cancer
|
resistant
|
Pacritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835V demonstrated resistance to Vonjo (pacritinib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D839G
|
hematologic cancer
|
sensitive
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 D839G were sensitive to Crenolanib (CP-868596) treatment in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins
|
hematologic cancer
|
sensitive
|
Momelotinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Momelotinib (CYT387) decreased phosphorylation of Flt3 and Stat5 and inhibited proliferation of transformed cells expressing a FLT3-ITD mutation in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L FLT3 D835Y
|
hematologic cancer
|
resistant
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD, FLT3 F691L, and FLT3 D835Y demonstrated resistance to Crenolanib (CP-868596) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L FLT3 D835Y
|
hematologic cancer
|
resistant
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD, FLT3 F691L, and FLT3 D835Y demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D839G
|
hematologic cancer
|
sensitive
|
Momelotinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Momelotinib (CYT387) decreased phosphorylation of Flt3 and Stat5 and inhibited proliferation of transformed cells expressing FLT3-ITD and FLT3 D839G in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D839G
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) inhibited proliferation of transformed cells expressing FLT3-ITD and FLT3 D839G in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L FLT3 Y842H
|
hematologic cancer
|
resistant
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD, FLT3 F691L, and FLT3 Y842H demonstrated resistance to Crenolanib (CP-868596) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L FLT3 D835Y
|
hematologic cancer
|
resistant
|
Pacritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD, FLT3 F691L, and FLT3 D835Y demonstrated resistance to Vonjo (pacritinib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D835V
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835V were sensitive to Rydapt (midostaurin) treatment in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L FLT3 D835Y
|
hematologic cancer
|
resistant
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing FLT3-ITD, FLT3 F691L, and FLT3 D835Y demonstrated resistance to Vanflyta (quizartinib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins
|
acute myeloid leukemia
|
sensitive
|
Momelotinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Momelotinib (CYT387) inhibited proliferation of acute myeloid leukemia cell lines and patient-derived cells harboring FLT3-ITD mutations in culture, and resulted in prolonged survival and reduced leukemic burden in cell line xenograft models (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L
|
hematologic cancer
|
conflicting
|
Pacritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 F691L demonstrated resistance to Vonjo (pacritinib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D835V
|
hematologic cancer
|
sensitive
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 D835V were sensitive to Crenolanib (CP-868596) treatment in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L FLT3 Y842H
|
hematologic cancer
|
resistant
|
Pacritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD, FLT3 F691L, and FLT3 Y842H demonstrated resistance to Vonjo (pacritinib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D835V
|
hematologic cancer
|
resistant
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835V demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L
|
hematologic cancer
|
predicted - resistant
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 F691L, and FLT3 D835Y were resistant to Crenolanib (CP-868596) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 Y842H
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 Y842H were sensitive to Rydapt (midostaurin) treatment in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D835Y
|
hematologic cancer
|
sensitive
|
Crenolanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 D835Y were sensitive to Crenolanib (CP-868596) treatment in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L FLT3 D835Y
|
hematologic cancer
|
resistant
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD, FLT3 F691L, and FLT3 D835Y demonstrated resistance to Xospata (gilteritinib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D835Y
|
hematologic cancer
|
conflicting
|
Pacritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835Y demonstrated resistance to Vonjo (pacritinib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L FLT3 Y842H
|
hematologic cancer
|
resistant
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD, FLT3 F691L, and FLT3 Y842H demonstrated resistance to Xospata (gilteritinib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D835Y
|
hematologic cancer
|
sensitive
|
Midostaurin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835Y were sensitive to Rydapt (midostaurin) treatment in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D835V
|
hematologic cancer
|
sensitive
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lestaurtinib (CEP-701) inhibited proliferation of transformed cells expressing FLT3-ITD and FLT3 D835V in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L
|
hematologic cancer
|
resistant
|
Lestaurtinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 F691L demonstrated resistance to Lestaurtinib (CEP-701) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L FLT3 Y842H
|
hematologic cancer
|
resistant
|
Quizartinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed hematologic cells expressing FLT3-ITD, FLT3 F691L, and FLT3 Y842H demonstrated resistance to Vanflyta (quizartinib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 Y842H
|
hematologic cancer
|
resistant
|
Sorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 Y842H demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D835Y
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) inhibited proliferation of transformed cells expressing FLT3-ITD and FLT3 D835Y in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 F691L
|
hematologic cancer
|
resistant
|
Momelotinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 F691L demonstrated resistance to Momelotinib (CYT387) in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 Y842H
|
hematologic cancer
|
sensitive
|
Gilteritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Xospata (gilteritinib) inhibited proliferation of transformed cells expressing FLT3-ITD and FLT3 Y842H in culture (PMID: 34768286).
|
34768286
|
JAK2 V617F
|
hematologic cancer
|
sensitive
|
Momelotinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Momelotinib (CYT387) inhibited proliferation of transformed cells expressing JAK2 V617F in culture (PMID: 34768286).
|
34768286
|
FLT3 exon 14 ins FLT3 D839G
|
hematologic cancer
|
resistant
|
Pacritinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D839G demonstrated resistance to Vonjo (pacritinib) in culture (PMID: 34768286).
|
34768286
|